Fatal Hepatic Failure Associated with Graft Rejection Following Reduced-intensity Stem-cell Transplantation for Chronic Idiopathic Myelofibrosis (CIMF)

A 54-year-old man with chronic idiopathic myelofibrosis (CIMF) underwent RIST. His clinical course had been uneventful until day 60, when splenomegaly reappeared. Hepatic dysfunction developed on day 75. Recipient-type hematopoiesis increased to 51% on day 90. After rapid tapering of cyclosporin, serum levels of AST and ALP normalized in parallel with recovery of complete chimerism on day 134. Yet, jaundice progressed. He died of liver failure on day 176. Postmortem examination revealed neither GVHD nor VOD. Graft rejection following RIST for CIMF may lead to fatal hepatic damage through extramedullary hematopoiesis in the liver or cytokine-mediated immune dysregulations.

[1]  G. Barosi,et al.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2006, Current opinion in hematology.

[2]  H. Deeg,et al.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis. , 2003, Blood.

[3]  M. Sykes,et al.  Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. , 2003, Blood.

[4]  W Hasegawa,et al.  Stem cell transplantation for myelofibrosis: a report from two Canadian centers , 2003, Bone Marrow Transplantation.

[5]  N. Kröger,et al.  Dose‐reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia , 2002, British journal of haematology.

[6]  A. Verma,et al.  Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. , 2002, Blood.

[7]  S. Saidman,et al.  Achievement of sustained remissions despite loss of donor chimerism in patients with chemotherapy-refractory non-Hodgkins lymphoma treated with nonmyeloablative conditioning and allogeneic stem cell transplantation , 2001 .

[8]  A. Tefferi.  Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[9]  H. Deeg,et al.  Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. , 1999, Blood.

[10]  P. Morel,et al.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.

[11]  D. Snover.  Biopsy interpretation in bone marrow transplantation. , 1989, Pathology annual.

[12]  S. P. Levine,et al.  Massive hepatomegaly following splenectomy for myeloid metaplasia. Case report and review of the literature. , 1987, The American journal of medicine.